{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:07Z","timestamp":1791869107052,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115342","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:22:23Z","timestamp":1741346543000},"page":"115342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7531-7817","authenticated-orcid":false,"given":"Erman","family":"Akkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115342_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115342_bib2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP Study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115342_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/oncolo\/oyad202","article-title":"Reevaluating adjuvant capecitabine for resected biliary tract cancer","volume":"29","author":"Benjamin","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115342_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115342_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2025.115342_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115342_bib7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2025.115342_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115342_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231163785","article-title":"Adjuvant therapy of biliary tract cancers","volume":"15","author":"Kefas","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2025.115342_bib10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3748\/wjg.v28.i9.948","article-title":"Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma","volume":"28","author":"Liu","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2025.115342_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.surg.2022.11.027","article-title":"Major complications and mortality after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"173","author":"van Keulen","year":"2023","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2025.115342_bib12","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/liv.16047","article-title":"Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: setting the scene for new randomized evidence","volume":"44","author":"Salani","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.ejca.2025.115342_bib13","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/JS9.0000000000002161","article-title":"The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: a systematic review and network meta-analysis of randomized clinical trials","volume":"111","author":"Peng","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejca.2025.115342_bib14","article-title":"Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2025.115342_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2025.115342_bib16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.ejca.2025.115342_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2025.115342_bib18","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.ejca.2025.115342_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"key":"10.1016\/j.ejca.2025.115342_bib20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Glob Spine J"},{"key":"10.1016\/j.ejca.2025.115342_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.ejca.2025.115342_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ejca.2025.115342_bib23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115342_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2025.115342_bib25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115342_bib26","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115342_bib27","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.3748\/wjg.v21.i14.4358","article-title":"Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis","volume":"21","author":"He","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2025.115342_bib28","article-title":"Cell of origin in biliary tract cancers and clinical implications","volume":"3","author":"Moeini","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ejca.2025.115342_bib29","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2003.11.054","article-title":"Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center","volume":"21","author":"Gill","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:46:23Z","timestamp":1760640383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"alternative-id":["S0959804925001236"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115342","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115342"}}